(19) | |
| (11) | EP 0 298 654 A3 |
(12) | EUROPEAN PATENT APPLICATION |
(88) | Date of publication A3: | | 07.02.1990 Bulletin 1990/06 |
(43) | Date of publication A2: | | 11.01.1989 Bulletin 1989/02 |
(22) | Date of filing: 30.06.1988 |
| |
(84) | Designated Contracting States: | | AT BE CH DE ES FR GB GR IT LI LU NL SE |
(30) | Priority: | 07.07.1987 US 71861 18.04.1988 US 182530 21.06.1988 US 205748
|
(71) | Applicant: HYBRISENS LTD. | | Toronto
Ontario M3J 1P3 (CA) |
| (72) | Inventors: | | - Shami, Ezekiel Y.
Toronto
Ontario (CA) - Rothstein, Aser
Toronto
Ontario (CA) - Ramjeesingh, Mohabir
Mississaugu
Ontario (CA)
|
(74) | Representative: Arthur, Bryan Edward et al | | Withers & Rogers
4 Dyer's Buildings
Holborn London EC1N 2JT London EC1N 2JT (GB) |
|
| |
(54) | Use of antibody/antigen interactions to protect or modulate biological activity |
(57) A complex can be produced, comprising (i) an molecule having a biological activity and (ii) an antibody entity recognizing the molecule, that displays biological activity which is inactivation-resistant, relative to that of the molecule. The biologically active molecule can be an enzyme, for example, and can be used to produce a complex with an antibody or antigen-binding protein that resists inactivation resulting from a physical, chemical or biological process. Thus, the inactivation-resistant complex displays prolonged activity under conditions characterized by disrupting temperature, the presence of a proteolytic enzyme, disrupting pH, the presence of an oxidizing agent and/or the presence of an alcohol, among others.